Rubicon Organics: From Single-Site Grower to Two-Facility Premium Platform
Record Q2 revenue, first Cascadia sales, and a 20% yield jump at Pacifica signal a new growth phase.
ROMJ.V · Earnings Call · 2026-08-12
Rubicon Organics' Q2 2026 results are more than a record topline -- they mark the moment the company's two-year bet on scale started paying off. Revenue hit $18.5 million, up 23% year over year and 35% sequentially. But the numbers that really matter are the operational ones: a ~20% yield improvement at its Pacifica facility, the first revenue from the newly operational Cascadia facility, and a gross margin that, excluding pre-revenue costs, reached 36% -- the best since Q4 2024.
The yield story is central. CEO Margaret Brodie broke down the drivers: “It is not all Pacifica biomass. We do have a vape portfolio and edibles, but then the large portion and the largest driver of our increase was specific yields.” — Margaret Ruth Brodie, CEO · 2026-08-12 The 20% yield jump came from a combination of cultivation enhancements, process improvements, and the genetic library that has become the company's signature advantage. The same playbook is now being applied at Cascadia, which just delivered its first $450k of revenue late in the quarter. CFO Glenn Ibbott was explicit that the ramp is ahead of plan: “Importantly, for future quarters, Cascadia has begun to move from a pre revenue investment phase to a revenue-generating part of our platform.” — William Glenn Ibbott, CFO · 2026-08-12 This is a stark contrast to a year ago, when capacity was the binding constraint. As Brodie noted in August 2025: “we've been able to grow the business, certainly well over double digits. every year, and that's through innovation and looking at new product lines.” — Margaret Ruth Brodie, CEO · 2025-08-18 That innovation-led growth is now being supercharged by the yield gains. The two-facility model is not just about capacity. It gives Rubicon the ability to match cultivars to the environment where they perform best, a nuanced advantage in a market where consistency is the currency. Brodie described it as: “Our 2-facility platform allows us to leverage our genetics program advantage more effectively than ever before.” — Margaret Ruth Brodie, CEO · 2026-08-12 That platform now supports annual production capacity of ~15,500 kilos, with a clear path to 20,000 within 18-24 months -- a plan that requires only modest CapEx and is driven by the same yield levers that worked at Pacifica. The genetics focus has been a longstanding bullish thesis: “We believe our genetics, the positioning that we're in and our brand strength, we expect to continue to grow share.” — Margaret Brodie, CEO · 2025-05-28 Now it has a second facility to operationalize it. International expansion is another leg of the story. The international market is still nascent for Rubicon, but the UK launch of the 1.91 thousand brand and the GACP certification for Cascadia set up a meaningful channel. Margaret expects international revenue to be ~10% of total for 2026, with more markets on the horizon. This is a deliberate brand-building move, not just wholesale peddling. On margins, the company is chasing 40%+ gross margin, and the levers are visible: Pre Roll automation (three machines now operational), in-house hydrocarbon extraction by year-end, and continued yield gains. Ibbott said: “we have got 3 automate automated pre roller machines now in production. that is all new this year. We talked about the hydrocarbon project, you know, juicing it ourselves internally, you know, we will move our margins on vapes up significantly.” — William Glenn Ibbott, CFO · 2026-08-12 These are operating leverage plays, not pricing gambits, which is exactly what a company with this cost structure needs. The balance sheet remains tight -- $3M cash, $20.9M working capital -- but positive adjusted EBITDA of $1.1M shows the model works even before the full Cascadia contribution. The real test comes in H2 2026, when revenue is expected to ramp progressively. As Brodie put it: “we remain focused on execution, and we believe we are well positioned to drive further growth opportunities in margin, revenues and cash flow through the second half of 26 and beyond.” — Margaret Ruth Brodie, CEO · 2026-08-12 Compared to prior quarters, the tone has shifted from "we are capacity constrained" to "we are now unlocking capacity." In the August 2025 call, Brodie talked about buying 2,000 kg of biomass and the uncertainty of when new capacity would come online. Now, the conversation is about optimizing yields and margin expansion. The company is still small (market cap under $30M) and execution risk is real, but the trajectory is unmistakable: a single-site premium grower is becoming a two-facility, internationally exposed player. That is a meaningful change, and it's the reason this quarter matters.We delivered record Q2 net revenue of $18.5 million representing 23% growth year over year and 35% growth sequentially.